News ListMonday 30. of August 2010 IPSOGEN Strengthens its Patent Position with U.S. Allowance of Additional JAK2 V617F ClaimsIPSOGEN (Alternext - FR0010626028 - ALIPS) announced today that the United States Patent and Trademark Office (USPTO) has allowed claims that strengthen the company’s patent position for the detection and diagnostic use of the... Category: Leukemia
 Thursday 17. of June 2010 Ipsogen announces the success of a € 1.9 million reserved capital increaseMarseille, 17 June 2010 - IPSOGEN (the « Company » ; Alternext - FR0010626028 – ALIPS), a cancer «profiler» company that develops, manufactures and markets molecular diagnostic tests for leukemia and breast cancer, today... Category: Investors
 Tuesday 20. of April 2010 IPSOGEN to hold its Annual General Meeting of Shareholders on May 12, 2010, in Marseilles, FranceNotice of Meeting of this Shareholders’ AGM published in the French official legal bulletin (“BALO”). More Category: Investors
Wednesday 07. of April 2010 Next Events and Congresses (Q2 2010)Ipsogen is pleased to support scientific community actions by participating and sponsoring networks of excellence and scientific conferences • COST Action BM0902 MPN/MPNr-EuroNet MPN&MPNr-EuroNet will hold... Monday 15. of March 2010 2009 annual resultsRevenue growth of 63% associated with a substantial development of sales of the JAK2 test, notably in the United StatesIncrease in operating expenses, essentially associated with the announced strengthening of sales teams, in... Category: Investors
Thursday 04. of March 2010 Ipsogen appoints Corinne Danan as Vice President Commercial OperationsIPSOGEN announces today that Corinne Danan has joined the company as Vice President Commercial Operations to develop Ipsogen presence in Europe and rest of the world.More Category: Corporate
 Wednesday 17. of February 2010 2009 revenue totaled €6.7 millionUp 63% on the previous financial year and up 60% at constant forex Category: Investors
Monday 25. of January 2010 IPSOGEN Obtains Option to Acquire License on TET2 abnormalities to improve the Diagnosis of Blood-based DisordersIPSOGEN today announces the signature of an option agreement for the worldwide and exclusive license on genomic abnormalities in the TET2 gene. The scientific corpus supporting these TET2 patent rights has been developed by a... Category: Leukemia
Monday 11. of January 2010 The Institut Curie and IPSOGEN sign a scientific collaboration agreement relating to the Genomic Grade, a molecular diagnostic tool for breast cancerParis, Marseille, January 11, 2010 - The INSTITUT CURIE and IPSOGEN (FR0010626028 - ALIPS) announce the signing of a scientific collaboration agreement in the breast cancer domain. Within the framework of this project, the... Category: Breast Cancer
 |
|
